Shandong Xinhua Pharmaceutical Co (SZSE:000756) LT-Debt-to-Total-Asset : 0.10 (As of Dec. 2023)

View and export this data going back to 1997. Start your Free Trial

What is Shandong Xinhua Pharmaceutical Co LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Shandong Xinhua Pharmaceutical Co's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.10.

Shandong Xinhua Pharmaceutical Co's long-term debt to total assets ratio increased from Dec. 2022 (0.07) to Dec. 2023 (0.10). It may suggest that Shandong Xinhua Pharmaceutical Co is progressively becoming more dependent on debt to grow their business.

Shandong Xinhua Pharmaceutical Co LT-Debt-to-Total-Asset Historical Data

The historical data trend for Shandong Xinhua Pharmaceutical Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shandong Xinhua Pharmaceutical Co LT-Debt-to-Total-Asset Chart

Shandong Xinhua Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.09

0.07

0.05

0.07

0.10

Shandong Xinhua Pharmaceutical Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.07	0.13	0.10	0.10	0.10

Shandong Xinhua Pharmaceutical Co LT-Debt-to-Total-Asset Calculation

Shandong Xinhua Pharmaceutical Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	800.979	/	8286.166
	=	0.10

Shandong Xinhua Pharmaceutical Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )	/	Total Assets (Q: Dec. 2023 )
	=	800.979	/	8286.166
	=	0.10

Shandong Xinhua Pharmaceutical Co (SZSE:000756) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Shandong Xinhua Pharmaceutical Co LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Shandong Xinhua Pharmaceutical Co's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Shandong Xinhua Pharmaceutical Co (SZSE:000756) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shandong Xinhua Pharmaceutical Co Ltd (SZSE:000756) » Definitions » LT-Debt-to-Total-Asset

Traded in Other Exchanges

00719:Hong Kong XIN:Germany

Address

No. 1 Lutai Avenue, Hi-tech Industry Development Zone, Zibo City, Shandong, CHN, 255086

Website

http://www.xhzy.com

Shandong Xinhua Pharmaceutical Co Ltd is a pharmaceutical products manufacturer based in China. It operates the business through the following segments: Chemical bulk drugs, Preparations, Chemical intermediates, and other products. The company provides chemical bulk drug products, including metamizole sodium, caffeine, aminopyrine, aspirin, hydrocortisone, pipemidic acid, ibuprofen, and L-dopa, it also dispenses formulation products such as compound liquorice tablets and nimodipine tablets. Its products address disorders related to the central nervous system and the cerebrovascular system with the help of antipyretics and analgesics.

Shandong Xinhua Pharmaceutical Co (SZSE:000756) Headlines

No Headlines